Certara, Inc. Strategic Update and Q1 2026 Financials

We have broken down the latest news from Certara, Inc. into plain English so you can understand what is happening and why it matters for your investment thesis.

1. What happened?

Certara sold its "medical writing and regulatory services" business to Veristat, a clinical research firm. Alongside this sale, the company reported its first-quarter results for 2026. Certara reported a loss of $8.8 million this quarter, compared to a $4.7 million profit in the same period last year. This loss was primarily driven by $13.5 million in one-time costs related to the sale and company reorganization, as well as higher executive and stock-based compensation.

2. Why is this happening?

New CEO Jon Resnick is aggressively shifting the company’s focus toward its high-margin biosimulation software and technology services. By selling the labor-heavy medical writing division, Certara is simplifying its operations. The sale brought in $85 million in cash, which strengthens the balance sheet and provides capital to accelerate investments in AI-driven drug development.

3. Why does this matter for investors?

Certara is "pruning" its business to boost long-term profitability. While the recent loss reflects one-time transition costs, the core software business is performing well, with bookings up 20% this quarter. The market is now looking at a "new" Certara that is moving away from manual, document-heavy work toward a more scalable, software-focused model.

4. Who is affected?

• Investors: The company’s revenue mix is fundamentally changing. With the regulatory business gone, Certara expects a 50/50 split between software and services revenue. Keep an eye on the full-year growth target of 0%–4% to see if the software business can successfully offset the lost revenue from the divested unit.
• Customers: Clients who previously used Certara for medical writing and regulatory support have transitioned to Veristat.
• Employees: Staff from the sold division have moved to Veristat, while Certara’s internal focus is now heavily concentrated on AI and biosimulation talent.

5. What should you watch for next?

• The "New" Baseline: The company expects 2026 revenue to land between $395 million and $405 million.
• Software Growth: Software is the primary growth engine, with revenue up 7% year-over-year. Watch to see if this growth rate accelerates as the company focuses its resources.
• Profitability: The company is currently absorbing transition costs. Look for stable profit margins (specifically Adjusted EBITDA) in the 30%–32% range as the business becomes more efficient.
• Potential Upside: Certara could receive an additional $35 million "earn-out" payment if the sold business performs well under Veristat’s ownership.

Bottom Line for Investors

Certara is in the middle of a strategic pivot. The short-term financial results look messy due to the costs of selling off a division, but the long-term goal is to become a leaner, software-centric company. If you are considering an investment, focus on whether the software segment can maintain its momentum and if the company can successfully hit its 30%+ EBITDA margin targets in the coming quarters.

Disclaimer: This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.